These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12477997)

  • 21. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
    Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
    Sutton G; Blessing JA; Park R; DiSaia PJ; Rosenshein N
    Obstet Gynecol; 1996 May; 87(5 Pt 1):747-50. PubMed ID: 8677079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
    Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.
    Lhommé C; Vennin P; Callet N; Lesimple T; Achard JL; Chauvergne J; Luporsi E; Chinet-Charrot P; Coudert B; Couette JE; Guastalla JP; Lebrun D; Ispas S; Blumberg J
    Gynecol Oncol; 1999 Nov; 75(2):187-93. PubMed ID: 10525370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study.
    Fracasso PM; Blessing JA; Molpus KL; Adler LM; Sorosky JI; Rose PG
    Gynecol Oncol; 2006 Nov; 103(2):523-6. PubMed ID: 16712905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
    Fernandez del Moral P; Dijkman GA; Debruyne FM; Witjes WP; Kolvenbag GJ
    Urology; 1996 Dec; 48(6):894-900. PubMed ID: 8973673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
    Fazeny B; Baur M; Prohaska M; Hudec M; Kremnitzer M; Meryn S; Huber H; Grunt T; Tuchmann A; Dittrich C
    J Cancer Res Clin Oncol; 1997; 123(1):45-52. PubMed ID: 8996540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
    Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
    J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).
    Pandya KJ; Yeap BY; Weiner LM; Krook JE; Erban JK; Schinella RA; Davis TE
    Am J Clin Oncol; 2001 Feb; 24(1):43-6. PubMed ID: 11232948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
    Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.
    Leiser AL; Hamid AM; Blanchard R
    Gynecol Oncol; 2004 Aug; 94(2):567-71. PubMed ID: 15297205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
    van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
    Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study.
    Donnez J; Vilos G; Gannon MJ; Stampe-Sorensen S; Klinte I; Miller RM
    Fertil Steril; 1997 Jul; 68(1):29-36. PubMed ID: 9207580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
    Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
    J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal therapy of endometrial stromal sarcoma.
    Reich O; Regauer S
    Curr Opin Oncol; 2007 Jul; 19(4):347-52. PubMed ID: 17545798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.